Skip to content
← Catalog

Interius BioTherapeutics · in vivo CAR-T (acquired by Kite/Gilead)

Interius BioTherapeutics · in vivo CAR-T 公司 · lentiviral delivery · 2025 被 Kite (Gilead 子公司) 以 $350M 收购(per OPORD-002 verify priority)。 对 SunVax 的对标:lentiviral 而非 LNP · 不同 modality 但同 in vivo cell engineering 大方向。

Type
company
Domain
conference
Grade
conference
License
LIGHT_HOPE_proprietary
evidence_grade
B
category
in_vivo_car_t_lentiviral
status
draft
instance_tag
sunvax-antibody-2025
platform_tech
lentiviral · in vivo CAR-T
acquisitions
[object Object]

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.